Scarica l'app Stockscreener
5.45
0.18%
-0.010
Precedente Chiudi:
$5.46
Aprire:
$5.46
Volume 24 ore:
319.71K
Relative Volume:
0.26
Capitalizzazione di mercato:
$1.22B
Reddito:
$596.48M
Utile/perdita netta:
$123.72M
Rapporto P/E:
9.938
EPS:
0.5484
Flusso di cassa netto:
$106.59M
1 W Prestazione:
-0.91%
1M Prestazione:
+1.11%
6M Prestazione:
+66.16%
1 anno Prestazione:
+68.73%
Intervallo 1D:
$5.44
$5.46
Intervallo di 1 settimana:
$5.44
$5.535
Portata 52W:
$2.37
$5.72
Curevac N V Stock (CVAC) Company Profile
Confronta CVAC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CVAC
Curevac N V
|
5.45 | 1.23B | 596.48M | 123.72M | 106.59M | 0.5484 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.36 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.01 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.31 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.97 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.33 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Curevac N V Stock (CVAC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-04-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2023-06-08 | Iniziato | SVB Securities | Outperform |
| 2023-01-19 | Aggiornamento | UBS | Neutral → Buy |
| 2023-01-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Hold |
| 2021-06-17 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-04-26 | Ripresa | Credit Suisse | Underperform |
| 2021-04-26 | Iniziato | Guggenheim | Neutral |
| 2020-12-10 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2020-09-08 | Iniziato | BofA Securities | Buy |
| 2020-09-08 | Iniziato | Credit Suisse | Neutral |
| 2020-09-08 | Iniziato | Jefferies | Hold |
Mostra tutto
Curevac N V Borsa (CVAC) Ultime notizie
CureVac NV earnings missed by €0.21, revenue fell short of estimates - Investing.com Australia
CureVac: Despite weak Q2, acquisition remains on track - MarketScreener
Is CureVac N.V. stock bottoming out2025 Trading Recap & Consistent Growth Stock Picks - Newser
CureVac N.V. Volume Confirms Breakout — Analysts BullishDay Trade & Expert Verified Stock Movement Alerts - classian.co.kr
Investors Hope for Bounce in CureVac N.V. After Selloff2025 Market Trends & High Conviction Buy Zone Picks - metal.it
Published on: 2025-08-17 02:22:48 - Newser
What to do if you’re stuck in CureVac N.V.2025 Year in Review & Daily Momentum Trading Reports - Newser
Will breakout in CureVac N.V. lead to full recoveryJuly 2025 Spike Watch & Accurate Buy Signal Alerts - Newser
CureVac Reports Financial Losses in Mid-2025 - MSN
Is it time to cut losses on CureVac N.V.Market Movers & Fast Entry High Yield Tips - Newser
Is CureVac N.V. part of any ETFJuly 2025 Catalysts & Precise Buy Zone Identification - classian.co.kr
Will CureVac N.V. price bounce be sustainableJuly 2025 WrapUp & Verified Chart Pattern Signals - Newser
CureVac N.V. Stages Intraday Comeback — Trend Change2025 Institutional Moves & High Accuracy Trade Signal Alerts - 선데이타임즈
Is a relief rally coming for CureVac N.V. holders2025 Market Trends & Fast Entry Momentum Trade Alerts - Newser
How high can CureVac N.V. stock goWeekly Investment Report & Free Risk Controlled Daily Trade Plans - Newser
CureVac's Q2 Pre-Tax Loss Narrows, Revenue Falls - MarketScreener
Earnings Flash (CVAC) CureVac Posts Q2 Revenue 1.2M Euros, vs. FactSet Est of 3.3M Euros - MarketScreener
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates | CVAC Stock News - GuruFocus
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates - ACCESS Newswire
$740M Patent Settlement: CureVac Resolves Pfizer Dispute and Agrees to BioNTech Acquisition Deal - Stock Titan
How does CureVac N.V. compare to its peersExit Point & Risk Managed Investment Strategies - thegnnews.com
Is There Enough Volume to Lift CureVac N.V.Weekly Market Report & Free Long-Term Investment Growth Plans - newsyoung.net
CureVac (CVAC) to Release Earnings on Thursday - Defense World
How CureVac N.V. stock performs during market volatilityPrice Forecast Based on AI Analysis - Newser
CureVac NV expected to post a loss of 18 cents a shareEarnings Preview - TradingView
CureVac N.V. (NASDAQ:CVAC) Holdings Raised by Zurcher Kantonalbank Zurich Cantonalbank - Defense World
mRNA Cancer Vaccine Market Is Going to Boom | Major Giants BioNTech, Moderna, CureVac, Gilead Sciences - newstrail.com
Key resistance and support levels for CureVac N.V.High Return Strategy with Low Risk - Newser
Analyzing CureVac (NASDAQ:CVAC) & ARAVIVE (NASDAQ:ARAV) - Defense World
Can CureVac N.V. keep up with sector leadersSmart Money ROI Picks - sisain.net
GSK set to get $500 million from settlement of mRNA lawsuit - The Economic Times
Can a trend reversal in CureVac N.V. lead to recoverySmart Swing Picks with Confirmed Signals - Newser
BioNTech (BNTX) Settles mRNA Patent Dispute with CureVac for US$370 Million - Yahoo Finance
BioNTech ends patent fight with mRNA rival CureVac ahead of buyout deal - BioPharma Dive
Drawdown in CureVac N.V. May Be Nearing EndFast Gaining Stock Screener Reports Released - beatles.ru
GSK Secures $370 Million In MRNA Patent Settlement Windfall - Finimize
CureVac Enters Agreements to Resolve mRNA Patent Litigation with Pfizer/BioNTech - Contract Pharma
CureVac announces resolution of patent litigation with Pfizer/BioNTech - Medical Dialogues
CureVac (CVAC) Secures $740M from Patent Settlement with Pfizer and BioNTech - GuruFocus
GSK plc Provides Update on US Settlement of CureVac/BioNTech mRNA Patent litigation - MarketScreener
GSK, CureVac to receive $740M as COVID vaccine patent dispute with Pfizer, BioNTech settled - Seeking Alpha
GSK to be paid up to £370 million after patent row settles in US - uk.finance.yahoo.com
GSK: $370m received as part of CureVac/BioNTech agreement - MarketScreener
mRNA rivals call truce as BioNTech prepares CureVac takeover - MarketScreener
GSK wins settlement, future royalties in CureVac mRNA patent dispute - MarketScreener
GSK Set for $500 Million Payment From mRNA Lawsuit Settlement - Bloomberg.com
GSK Reaches $500M Agreement Over Covid-19 Jab Patent Row - AInvest
GSK To Get $370 Mln Upfront Payment From CureVac With MRNA Patent Settlement - Nasdaq
Will CureVac N.V. stock benefit from AI tech trendsFast Gaining Stock Screener Reports Released - metal.it
BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth - Benzinga
How the U.S. mRNA Therapeutics Market Will Evolve by 2032 - openPR.com
Curevac N V Azioni (CVAC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.44%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):